Liu Bing Cheng
Liu Bing Cheng — Chief Physician — Leukemia Diagnosis and Treatment Center — Chinese Academy of Medical Sciences Hematology Hospital
Specialties
The diagnosis and treatment of hematologic diseases, including malignant hematologic disorders, myeloproliferative tumors, myelodysplastic syndromes, aplastic anemia, etc., especially the diagnosis and treatment of acute and chronic leukemia and myeloproliferative tumors.
Education
Graduated from Tongji Medical University in 1993 with a bachelor's degree, and graduated from China Union Medical University in July 2001 with a doctorate degree.
Professional Experience
Chief physician, Doctor of Medicine, Director of the Leukemia Diagnosis and Treatment Center Ward. Employed at the Hematology Hospital of the Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, engaged in clinical and research work on hematologic diseases. Specializes in clinical and basic research on chronic myeloid leukemia, focusing on the study of the anti-leukemia mechanism of imatinib. From January 2002 to December 2006, conducted postdoctoral research at the National Institutes of Health in the United States. Responsible for multiple clinical studies on the efficacy of tyrosine kinase inhibitors (imatinib, dasatinib, and nilotinib) in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Skilled in the diagnosis and treatment of acute leukemia, chronic myeloid leukemia, and myeloproliferative neoplasms.
Professional Roles
Standing member of the China Anti-Cancer Association's Integrative Traditional Chinese and Western Medicine Leukemia Professional Committee, standing member of the Leukemia Branch of the Chinese Medical Association, and member of the Hematology Expert Committee for patient assistance programs Gleevec, Dasatinib, Enzastaurin, and Iclusig of the China Charity Federation.